HOTH - Hoth Therapeutics rises 7% on expanded use of HT-003 in inflammatory bowel diseases

Hoth Therapeutics (HOTH) intends to expand the development of the HT-003 active pharmaceutical ingredient ((API)) to pursue a new indication for the treatment of inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis.Hoth executed an option agreement with Isoprene Pharmaceuticals to investigate the potential for HT-003 API as an IBD therapeutic.Recent data suggests that aberrant retinoic acid regulation may contribute to the underlying inflammatory mechanism that causes IBD symptoms, and restoring retinoic acid homeostasis may be beneficial. The API of HT-003 has demonstrated anti-inflammatory properties and targets retinoic acid metabolism pathway. Hoth plans to investigate the therapeutic potential of the HT-003 API using relevant ex vivo tissue models and other in vitro molecular studies.Last month, Hoth announced encouraging action of HT-003 in acne treatment.Shares up 7% premarket.

For further details see:

Hoth Therapeutics rises 7% on expanded use of HT-003 in inflammatory bowel diseases